ADC Pre-Clinical Development: Where Are We in 2023?

The current preclinical ADC landscape is experiencing a remarkable surge, marked by the emergence of 19 novel ADCs entering the clinic this year alone! 40 new ADC developers have vested interests in at least one ADC program this year, emphasizing the field’s impressive growth. Furthermore, over 70% of preclinical ADCs are classed as active, demonstrating evidence of continued development and instilling confidence for future developments.

In terms of top targets, the landscape is facing a notable shift. There has been a decline in new preclinical HER-2 ADCs, while two promising targets climb up the ranks as they gain popularity. Take a look at our infographic to reveal the latest top targets and steal a glimpse at the exciting breakthroughs that lie ahead…